1026473-02-8

Basic information

• Product Name: {(S)-5-[(S)-2-((S)-3-tert-Butoxycarbonylamino-2-oxo-4-phenyl-butylamino)-3-phenyl-propionylamino]-5-carbamoyl-pentyl}-carbamic acid benzyl ester
• Synonyms: {(S)-5-[(S)-2-((S)-3-tert-Butoxycarbonylamino-2-oxo-4-phenyl-butylamino)-3-phenyl-propionylamino]-5-carbamoyl-pentyl}-carbamic acid benzyl ester
• CAS NO: 1026473-02-8
• Molecular Weight: 687.836
• Mol File: 1026473-02-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {(S)-5-[(S)-2-((S)-3-tert-Butoxycarbonylamino-2-oxo-4-phenyl-butylamino)-3-phenyl-propionylamino]-5-carbamoyl-pentyl}-carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: {(S)-5-[(S)-2-((S)-3-tert-Butoxycarbonylamino-2-oxo-4-phenyl-butylamino)-3-phenyl-propionylamino]-5-carbamoyl-pentyl}-carbamic acid benzyl ester(1026473-02-8)
• EPA Substance Registry System: {(S)-5-[(S)-2-((S)-3-tert-Butoxycarbonylamino-2-oxo-4-phenyl-butylamino)-3-phenyl-propionylamino]-5-carbamoyl-pentyl}-carbamic acid benzyl ester(1026473-02-8)

Safety Data

• Hazardous Substances Data: 1026473-02-8(Hazardous Substances Data)

Upstream product

• 60398-41-6 (3S)-tert-butyl 1-benzyl-3-diazo-2-oxopropylcarbamate 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 102123-74-0 (S)-tert-butyl (4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate 

Relevant articles and documents

Synthesis and activity of HIV protease inhibitors

We report here the synthesis and activity of HIV protease inhibitors. In the first stage hydrophobic compounds incorporating a 'carba' bond surrogate or a beta-homologated residue were synthesized. Secondly, we synthesized cyclic compounds in which we incorporated 2-quinoline carboxylic acid in the P3 position and the amino-hydroxyindane moiety in the P'3. The last part of this work was dedicated to a structure/activity study of a peptide substrate. These modifications allowed us to work up the synthesis of new pseudopeptide bonds: amino-amide and hydroxy-amide. Compounds with activity in the micromolar range were actually a starting point for the synthesis of new protease inhibitors.